Home
/
Sunshine Biopharma Inc.
/
Financials
/
Quarterly
Sunshine Biopharma Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Sunshine Biopharma Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$9.42M
Nov 13, 2025
Q2
2025
Jun 30, 2025
$9.41M
Aug 12, 2025
Q1
2025
Mar 31, 2025
$8.90M
May 15, 2025
Q3
2025
Sep 30, 2024
$8.44M
Nov 13, 2025
Q2
2025
Jun 30, 2024
$9.30M
Aug 12, 2025
Q1
2025
Mar 31, 2024
$7.54M
May 15, 2025
Q3
2024
Sep 30, 2023
$5.96M
Nov 5, 2024
Q2
2024
Jun 30, 2023
$5.56M
Aug 20, 2024
Q1
2024
Mar 31, 2023
$4.89M
May 20, 2024
Q3
2023
Sep 30, 2022
$132.8K
Nov 13, 2023
Q2
2023
Jun 30, 2022
$150.3K
Aug 10, 2023
Q1
2023
Mar 31, 2022
$122.6K
May 10, 2023
Q3
2022
Sep 30, 2021
$50.4K
Nov 7, 2022
Q2
2022
Jun 30, 2021
$52.9K
Aug 3, 2022
Q1
2022
Mar 31, 2021
$40.1K
May 6, 2022
Q3
2021
Sep 30, 2020
$17.2K
Nov 9, 2021
Q2
2021
Jun 30, 2020
$15.1K
Aug 9, 2021
Q1
2021
Mar 31, 2020
$11.1K
May 11, 2021
Q3
2020
Sep 30, 2019
$7.3K
Nov 12, 2020
Q2
2020
Jun 30, 2019
$3.0K
Aug 31, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($883.8K)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($1.77M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($1.18M)
May 15, 2025
Q3
2025
Sep 30, 2024
($1.20M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($494.3K)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($1.28M)
May 15, 2025
Q3
2024
Sep 30, 2023
($651.5K)
Nov 5, 2024
Q2
2024
Jun 30, 2023
($902.1K)
Aug 20, 2024
Q1
2024
Mar 31, 2023
($1.70M)
May 20, 2024
Q3
2023
Sep 30, 2022
($1.46M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($538.9K)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($1.24M)
May 10, 2023
Q3
2022
Sep 30, 2021
($4.04M)
Nov 7, 2022
Q2
2022
Jun 30, 2021
($2.88M)
Aug 3, 2022
Q1
2022
Mar 31, 2021
($6.19M)
May 6, 2022
Q3
2021
Sep 30, 2020
($698.6K)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($907.4K)
Aug 9, 2021
Q1
2021
Mar 31, 2020
($94.3K)
May 11, 2021
Q3
2020
Sep 30, 2019
($350.2K)
Nov 12, 2020
Q2
2020
Jun 30, 2019
($710.9K)
Aug 31, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.09M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($2.05M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($1.30M)
May 15, 2025
Q3
2025
Sep 30, 2024
($1.11M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($1.27M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($1.35M)
May 15, 2025
Q3
2024
Sep 30, 2023
($779.5K)
Nov 5, 2024
Q2
2024
Jun 30, 2023
($1.01M)
Aug 20, 2024
Q1
2024
Mar 31, 2023
($1.83M)
May 20, 2024
Q3
2023
Sep 30, 2022
($1.72M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($695.8K)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($1.22M)
May 10, 2023
Q3
2022
Sep 30, 2021
($496.3K)
Nov 7, 2022
Q2
2022
Jun 30, 2021
($388.6K)
Aug 3, 2022
Q1
2022
Mar 31, 2021
($1.28M)
May 6, 2022
Q3
2021
Sep 30, 2020
($67.3K)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($128.6K)
Aug 9, 2021
Q1
2021
Mar 31, 2020
($37.7K)
May 11, 2021
Q3
2020
Sep 30, 2019
($202.6K)
Nov 12, 2020
Q2
2020
Jun 30, 2019
($66.2K)
Aug 31, 2020